Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan

CEO Dr. Amit Kumar outlines the company's strategy for advancing oncology programs while maintaining modest cash burn.

Apr. 17, 2026 at 9:11am

Got story updates? Submit your updates here. ›

An extreme close-up macro X-ray photograph revealing the intricate internal structure of a cancer cell, glowing with a ghostly, translucent quality against a dark background, conceptually representing the innovative cell-based immunotherapies Anixa Biosciences is developing.Anixa Biosciences' novel cell-based cancer therapies aim to harness the power of the immune system to fight solid tumors.Cleveland Today

Anixa Biosciences CEO Dr. Amit Kumar discussed the company's clinical-stage oncology programs, including a FSHR-targeted CAR-T therapy for late-stage ovarian cancer and a breast cancer vaccine entering Phase II, while emphasizing Anixa's lean operating model and partnership-driven approach to clinical development.

Why it matters

Anixa's focus on advancing innovative cancer therapies through strategic collaborations and a capital-efficient structure could make it an attractive biotech investment, especially if its CAR-T and vaccine programs continue to demonstrate promising results.

The details

Kumar highlighted Anixa's FSHR-targeted CAR-T program for late-stage ovarian cancer, noting the challenges of CAR-T in solid tumors but saying Anixa's approach, including local delivery into the peritoneum, has shown survival benefits. For the upcoming Phase II breast cancer vaccine study, Anixa plans to evaluate the vaccine in combination with standard-of-care KEYTRUDA in the neoadjuvant setting. Kumar also discussed Anixa's partnership-driven model, use of consultants, and plans to pursue pharmaceutical partnerships for commercialization.

  • Anixa expects to begin the Phase II breast cancer vaccine trial within the next 12 to 18 months.
  • Anixa plans to treat 9 more patients in upcoming cohorts of the CAR-T program and provide additional patient updates.

The players

Anixa Biosciences

A clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms.

Dr. Amit Kumar

CEO of Anixa Biosciences who outlined the company's strategy and clinical programs.

Cleveland Clinic

A collaborator with Anixa on one of its oncology programs.

Moffitt Cancer Center

A collaborator with Anixa on its clinical development efforts.

Robert Sassoon

Managing Director of Healthcare, Neurosciences, and Special Situations at Water Tower Research, who moderated the conference session with Dr. Kumar.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

Anixa expects to provide additional updates on its CAR-T program as it treats more patients in upcoming cohorts, and anticipates beginning the Phase II breast cancer vaccine trial within the next 12 to 18 months.

The takeaway

Anixa's focus on advancing innovative cancer therapies through strategic collaborations and a capital-efficient structure could make it an attractive biotech investment, especially if its CAR-T and vaccine programs continue to demonstrate promising results.